In vitro studies suggested that metformin inhibits cancer cell growth by activating adenosine monophosphate protein kinase (Ampk), by inactivating the mammalian target of rapamycin (mTOR), and also by decreasing the activity of the mTOR effector S6K1 [10], [11]. Here, MTOR is linked to cancer.